NcXHF

PERSONALIZED TREATMENT OF HEAD AND NECK CANCER
treatment by allowing for unbiased understanding of the effects
of a treatment on quality of life. 26
THE FUTURE OF PERSONALIZED MEDICINE
Genomic data is flowing at unprecedented rates. The biology
of HNSCC is being dissected in increasingly remarkable detail.
Smarter drugs are in the pipeline to cater treatment to the
specifıc genetic makeup of a patient’s tumor. Private enterprise
has embraced the genome era and begun construction
of giant silos of patient data. Precision medicine has reached
the mainstream and is being heralded as the next great step in
the “war on cancer.” However, signifıcant hurdles remain before
big data can be translated into better outcomes for patients
with cancer. Determining which elements of big data
are biologically and clinically relevant will require the development
of new analysis methods, changes in clinical trial design,
new infrastructure for data sharing, and, perhaps most
importantly, close collaboration between bioinformaticists,
oncologists, and the pharmaceutical industry.
ACKNOWLEDGMENTS
We would like to thank John Paul Shen for thoughtful review.
Disclosures of Potential Conflicts of Interest
Relationships are considered self-held and compensated unless otherwise noted. Relationships marked “L” indicate leadership positions. Relationships marked “I” are those held by an immediate
family member; those marked “B” are held by the author and an immediate family member. Institutional relationships are marked “Inst.” Relationships marked “U” are uncompensated.
Employment: None. Leadership Position: None. Stock or Other Ownership Interests: None. Honoraria: None. Consulting or Advisory Role: Ezra Cohen,
Eisai, AstraZeneca, Bristol-Myers Squibb, Merck, VentiRx, Novartis, Bayer. Speakers’ Bureau: Ezra Cohen, Bayer, Blodesix. Research Funding: None.
Patents, Royalties, or Other Intellectual Property: Andrew Gross, Patents, etc. (Provisional patient, “Iterative Feature Selection for the Development
of Prognostic Models”)(Inst). Expert Testimony: None. Travel, Accommodations, Expenses: None. Other Relationships: None.
References
1. Halevy A, Norvig P, Pereira F. The unreasonable effectiveness of data.
IEEE Intelligent Systems. 2009;24:8-12.
2. Carneiro HA, Mylonakis E. Google trends: a web-based tool for realtime
surveillance of disease outbreaks. Clinical Infectious Diseases. 2009;
49:1557-1564.
3. Lazer D, Kennedy R, King G, Vespignani A. Big data. The parable of
Google Flu: traps in big data analysis. Science. 2014;343:1203-1205.
4. Ogden GR, Kiddie RA, Lunny DP, Lane DP. Assessment of p53 protein
expression in normal, benign, and malignant oral mucosa. J Pathol.
1992;166:389-394.
5. Califano J, van der Riet P, Westra W, et al. Genetic progression model
for head and neck cancer: implications for fıeld cancerization. Cancer
Res. 1996;56:2488-2492.
6. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor
alpha and epidermal growth factor receptor messenger RNA are early
markers of carcinogenesis in head and neck cancer. Cancer Res. 1993;
53:3579-3584.
7. Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of
head and neck squamous cell carcinoma. Science. 2011;333:1157-1160.
8. Cancer Genome Atlas Network. Comprehensive genomic characterization
of head and neck squamous cell carcinomas. Nature. 2015;517:576-
582.
9. Sepiashvili L, Bruce JP, Huang SH, et al. Novel insights into head and
neck cancer using next-generation “omic” technologies. Cancer Res.
2015;75:480-486.
10. Hammerman PS, Hayes DN, Grandis JR. Therapeutic insights from
genomic studies of head and neck squamous cell carcinomas. Cancer
Discovery. (2015). doi:10.1158/2159-8290.CD-14-1205.
11. D’Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human
papillomavirus and oropharyngeal cancer. N Engl J Med. 2007;356:
1944-1956.
12. Seiwert TY, Zuo Z, Keck MK, et al. Integrative and comparative
genomic analysis of HPV-positive and HPV-negative head and neck
squamous cell carcinomas. Clin Cancer Res. 2015;21:632-641.
13. Lui VW, Hedberg ML, Li H, et al. Frequent mutation of the PI3K pathway
in head and neck cancer defınes predictive biomarkers. Cancer Discovery.
2013;3:761-769.
14. Gross AM, Orosco RK, Shen JP, et al. Multi-tiered genomic analysis of
head and neck cancer ties TP53 mutation to 3p loss. Nat Genet. 2014;
46:939-943.
15. Raju SC, Hauff SJ, Lemieux AJ, et al. Combined TP53 mutation/3p loss
correlates with decreased radiosensitivity and increased matrixmetalloproteinase
activity in head and neck carcinoma. Oral Oncol.
Epub 2015 Feb 27.
16. Li C, Egloff AM, Sen M, et al. Caspase-8 mutations in head and neck
cancer confer resistance to death receptor-mediated apoptosis and enhance
migration, invasion, and tumor growth. Molecular Oncology.
2014;8:1220-1230.
17. Mroz EA, Tward AM, Hammon RJ, et al. Intra-tumor genetic heterogeneity
and mortality in head and neck cancer: analysis of data from The
Cancer Genome Atlas. PLOS Medicine. 2015;12:e1001786.
18. Lawrence MS, Stojanov P, Mermel CH, et al. Discovery and saturation
analysis of cancer genes across 21 tumour types. Nature. 2014;
505:495-501.
19. Vitale-Cross L, Molinolo AA, Martin D, et al. Metformin prevents the development
of oral squamous cell carcinomas from carcinogen-induced
premalignant lesions. Cancer Prevention Research. 2012;5:562-573.
20. Poulikakos PI, Persaud Y, Janakiraman M, et al. RAF inhibitor resistance
is mediated by dimerization of aberrantly spliced BRAF(V600E).
Nature. 2011;480:387-390.
21. Collins FS, Varmus H. A new initiative on precision medicine. N Engl
J Med. 150130080035003 (2015). doi:10.1056/NEJMp1500523. Epub
2015 Jan 30.
asco.org/edbook | 2015 ASCO EDUCATIONAL BOOK 31